GlassScriptPhysician profile
James Oliviere
NPI 1891977146
$3,081.44
in general payments reported to CMS, 2019-2025
26 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $321 · 2021: $575 · 2022: $640 · 2023: $388 · 2024: $406 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.10 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $576.71 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Abbott Laboratories | $405.14 | 2021-2022 | |
| Novo Nordisk INC | $396.82 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $350.15 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $273.25 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $227.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.92 | 2021-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $99.56 | 2019-2021 | |
| Exact Sciences Corporation | $73.32 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $71.72 | 2019-2020 | |
| Welch Allyn | $60.00 | 2021 | |
| Glaxosmithkline, LLC. | $58.12 | 2023-2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $41.34 | 2020 | |
| Baxter Healthcare | $40.00 | 2022 | |
| Dexcom, INC. | $38.33 | 2023-2025 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $30.47 | 2023 | Auvelity |
| Genentech USA, INC. | $25.76 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $24.83 | 2024 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.86 | 2021 | |
| Aytu Biopharma, INC. | $19.55 | 2020 | |
| Lundbeck LLC | $16.98 | 2022 | |
| Linus Health, INC. | $15.11 | 2023 | |
| Amgen INC. | $13.86 | 2024 | Otezla, Repatha |
| Abbvie INC. | $12.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Oliviere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.